Whitepaper/App Note

Whitepaper: Predicting the release of active ingredients from sustained-release tablets

Posted: 1 May 2017 | | No comments yet

Near-infrared spectroscopy, used in combination with an appropriate calibration model, offers an alternative to dissolution testing, making it possible to predict the dissolution of tablets accurately and within a matter of minutes…

After taking a tablet, a phenomenon known as a plasma peak usually occurs: this is when the full amount of the drug is rapidly released from the tablet and the active ingredient concentration temporarily reaches a high level in the patient’s blood plasma as a result.

Depending on the type of drug, this high concentration can cause significant side-effects. In addition, a high administration frequency is required to produce a lasting effect, as the high plasma level that patients experience at the outset then falls rapidly again as the active ingredient is metabolized.

Sustained release reduces side-effects

Sustained-release formulations, which release active ingredients gradually, offer a solution to these issues. The occurrence of a plasma peak is prevented and a reasonable plasma level is maintained over a longer period. In particular, hormone preparations, drugs for regulating blood pressure, painkillers, and antidepressants are often administered in the form of sustained- release tablets.

This whitepaper is restricted to logged-in members. Login or become a member now (it's free!) to read it.


Related organisations

Send this to a friend